(Q34209887)

31 July 2017

title

Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration (English)

1 reference

31 July 2017

Matthew Hoffmann

1

1 reference

31 July 2017

Gondi Kumar

2

1 reference

31 July 2017

Peter Schafer

3

1 reference

31 July 2017

Dorota Cedzik

4

1 reference

31 July 2017

Lori Capone

5

1 reference

31 July 2017

Kei-Lai Fong

6

1 reference

31 July 2017

Zheming Gu

7

1 reference

31 July 2017

Dennis Heller

8

1 reference

31 July 2017

Hao Feng

9

1 reference

31 July 2017

Sekhar Surapaneni

10

1 reference

31 July 2017

Oscar Laskin

11

1 reference

31 July 2017

Anfan Wu

12

1 reference

31 July 2017

language of work or name

English

0 references

publication date

23 August 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

41

1 reference

31 July 2017

issue

12

1 reference

31 July 2017

page(s)

1063-1075

1 reference

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3231940

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3231940

Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3231940

Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3231940

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.3109%2F00498254.2011.604745

Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.3109%2F00498254.2011.604745

10.3109/00498254.2011.604745

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference